Transfusion and Haematology Today - Issue 4/2022
Review/Educational Papers
			
		   195
		
	
	
													
		
							Tixagevimab-cilgavimab eff ectiveness in preexposure prophylaxis and therapy in patients at high risk of COVID-19
					
					
B. Weinbergerová, T. Kabut, J. Mayer
Original Papers
			
		   203
		
	
	
																																																																																																																																																																																																																																																																																				
					
					
		
							How do anti-SARS-CoV-2 IgG and IgM predict the titre of virus-neutralizing antibodies in donors of convalescent plasma against COVID-19 disease?
					
					
A. Entrová, K. Azeem, J. Vlčková, J. Smital, S. Zatloukalová, J. Ševčíková, H. Kollárová, D. Horáková
			
		   213
		
	
	
													
		
							Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine – Haematology and Oncology in Brno
					
					
N. Podstavková, B. Weinbergerová, J. Procházková, M. Bohúnová, A. Marečková, J. Kotašková, I. Ježíšková, M. Doubek, J. Mayer
Case Report
			
		   221
		
	
	
																																																																		
					
					
		
							Haemolytic disease of the foetus and new-born
					
					
H. Kostrouchová, J. Tylečková, Romana Gerychová
			
		   228
		
	
	
													
		
							Beta-thalassemia minor and maior in pregnancy
					
					
Jana Racková, M. Mrázek
Letters to Editor
			
		   235
		
	
	
													Personal News
Transfusion and Haematology Today
					2022 Issue 4
Most read in this issue
- Haemolytic disease of the foetus and new-born
 - Beta-thalassemia minor and maior in pregnancy
 - Current experience with ropeginterferon Alfa-2b in Ph negative myeloproliferative neoplasm at the Department of Internal Medicine – Haematology and Oncology in Brno
 - How do anti-SARS-CoV-2 IgG and IgM predict the titre of virus-neutralizing antibodies in donors of convalescent plasma against COVID-19 disease?